SUSTAIN (A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SEIGI With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Administered By

Awarded By

Contributors

Start/End

  • February 1, 2014 - January 31, 2017